Chapman Ros, Jongwe Tsungai Ivai, Douglass Nicola, Chege Gerald, Williamson Anna-Lise
Institute of Infectious Disease and Molecular Medicine and Division of Medical Virology, Department of Pathology, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.
National Health Laboratory Services, Groote Schuur Hospital, Cape Town, South Africa.
PLoS One. 2017 Mar 9;12(3):e0173352. doi: 10.1371/journal.pone.0173352. eCollection 2017.
In an effort to make affordable vaccines suitable for the regions most affected by HIV-1, we have constructed stable vaccines that express an HIV-1 subtype C mosaic Gag immunogen (BCG-GagM, MVA-GagM and DNA-GagM). Mosaic immunogens have been designed to address the tremendous diversity of this virus. Here we have shown that GagM buds from cells infected and transfected with MVA-GagM and DNA-GagM respectively and forms virus-like particles. Previously we showed that a BCG-GagM prime MVA-GagM boost generated strong cellular immune responses in mice. In this study immune responses to the DNA-GagM and MVA-GagM vaccines were evaluated in homologous and heterologous prime-boost vaccinations. The DNA homologous prime boost vaccination elicited predominantly CD8+ T cells while the homologous MVA vaccination induced predominantly CD4+ T cells. A heterologous DNA-GagM prime MVA-GagM boost induced strong, more balanced Gag CD8+ and CD4+ T cell responses and that were predominantly of an effector memory phenotype. The immunogenicity of the mosaic Gag (GagM) was compared to a naturally occurring subtype C Gag (GagN) using a DNA homologous vaccination regimen. DNA-GagN expresses a natural Gag with a sequence that was closest to the consensus sequence of subtype C viruses sampled in South Africa. DNA-GagM homologous vaccination induced cumulative HIV-1 Gag-specific IFN-γ ELISPOT responses that were 6.5-fold higher than those induced by the DNA-GagN vaccination. Similarly, DNA-GagM vaccination generated 7-fold higher levels of cytokine-positive CD8+ T cells than DNA-GagN, indicating that this subtype C mosaic Gag elicits far more potent immune responses than a consensus-type Gag. Cells transfected and infected with DNA-GagM and MVA-GagM respectively, expressed high levels of GagM and produced budding virus-like particles. Our data indicates that a heterologous prime boost regimen using DNA and MVA vaccines expressing HIV-1 subtype C mosaic Gag is highly immunogenic in mice and warrants further investigation in non-human primates.
为了研发出适合受HIV-1影响最严重地区的平价疫苗,我们构建了稳定的疫苗,这些疫苗表达一种HIV-1 C亚型嵌合Gag免疫原(BCG-GagM、MVA-GagM和DNA-GagM)。嵌合免疫原的设计旨在应对该病毒的巨大多样性。在此我们已表明,GagM分别从感染和转染了MVA-GagM和DNA-GagM的细胞中出芽,并形成病毒样颗粒。此前我们表明,BCG-GagM初免-MVA-GagM加强免疫在小鼠中产生了强烈的细胞免疫反应。在本研究中,对DNA-GagM和MVA-GagM疫苗在同源和异源初免-加强接种中的免疫反应进行了评估。DNA同源初免-加强接种主要诱导CD8+ T细胞,而同源MVA接种主要诱导CD4+ T细胞。异源DNA-GagM初免-MVA-GagM加强免疫诱导了强烈、更平衡的Gag CD8+和CD4+ T细胞反应,且这些反应主要为效应记忆表型。使用DNA同源接种方案,将嵌合Gag(GagM)的免疫原性与天然存在的C亚型Gag(GagN)进行了比较。DNA-GagN表达一种天然Gag,其序列与在南非采样的C亚型病毒的共识序列最接近。DNA-GagM同源接种诱导的累积HIV-1 Gag特异性IFN-γ ELISPOT反应比DNA-GagN接种诱导的反应高6.5倍。同样,DNA-GagM接种产生的细胞因子阳性CD8+ T细胞水平比DNA-GagN高7倍,这表明这种C亚型嵌合Gag引发的免疫反应比共识型Gag强得多。分别用DNA-GagM和MVA-GagM转染和感染的细胞表达高水平的GagM,并产生出芽的病毒样颗粒。我们的数据表明,使用表达HIV-1 C亚型嵌合Gag的DNA和MVA疫苗的异源初免-加强方案在小鼠中具有高度免疫原性,值得在非人类灵长类动物中进一步研究。